Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,720,099
  • Shares Outstanding, K 63,660
  • Annual Sales, $ 18,660 K
  • Annual Income, $ -132,690 K
  • 60-Month Beta 1.62
  • Price/Sales 54.36
  • Price/Cash Flow N/A
  • Price/Book 127.52
Trade NVAX with:

Options Overview

Details
  • Implied Volatility 121.49%
  • Historical Volatility 204.04%
  • IV Percentile 41%
  • IV Rank 18.63%
  • IV High 408.43% on 03/11/20
  • IV Low 55.78% on 10/09/20
  • Put/Call Vol Ratio 0.75
  • Today's Volume 14,833
  • Volume Avg (30-Day) 22,007
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 89,111
  • Open Int (30-Day) 99,084

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -1.53
  • Number of Estimates 4
  • High Estimate -1.06
  • Low Estimate -1.76
  • Prior Year -1.13
  • Growth Rate Est. (year over year) -35.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
121.74 +89.94%
on 01/27/21
331.68 -30.29%
on 02/09/21
+104.07 (+81.84%)
since 01/26/21
3-Month
106.11 +117.92%
on 12/09/20
331.68 -30.29%
on 02/09/21
+128.63 (+125.37%)
since 11/25/20
52-Week
6.77 +3,315.51%
on 03/16/20
331.68 -30.29%
on 02/09/21
+222.01 (+2,407.92%)
since 02/26/20

Most Recent Stories

More News
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4

Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.

ENDP : 7.93 (-14.82%)
DVAX : 8.75 (+7.23%)
NVAX : 231.23 (+4.39%)
RGEN : 212.39 (+2.57%)
Novavax and Takeda Finalize License Agreement for Novavax' COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company...

NVAX : 231.23 (+4.39%)
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

Novavax (NVAX) closed the most recent trading day at $243.23, moving -0.76% from the previous trading session.

NVAX : 231.23 (+4.39%)
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

SNY : 45.89 (+0.20%)
NVAX : 231.23 (+4.39%)
XLRN : 136.16 (+0.21%)
TVTX : 30.82 (+3.77%)
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study...

NVAX : 231.23 (+4.39%)
Earnings Preview: Novavax (NVAX) Q4 Earnings Expected to Decline

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NVAX : 231.23 (+4.39%)
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico

- PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico

NVAX : 231.23 (+4.39%)
The Latest: Chinese, Russian vaccines to arrive in Mexico

MEXICO CITY — Mexico says it will get its first shipment of the Chinese Coronavac vaccine Saturday and by Monday will receive its first lot of the Russian Sputnik V shot. Both shipments are expected...

NVAX : 231.23 (+4.39%)
PFE : 33.49 (-0.98%)
JNJ : 158.46 (-2.64%)
Thinking about trading options or stock in Johnson & Johnson, Deere & Company, Apple, Novavax, or Niu Technologies?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JNJ, DE, AAPL, NVAX, and NIU.

AAPL : 121.26 (+0.22%)
NIU : 37.38 (+0.27%)
NVAX : 231.23 (+4.39%)
DE : 349.12 (+0.31%)
JNJ : 158.46 (-2.64%)
Dow Slips From Record Pace as Listless Week Continues

Dow Slips From Record Pace as Listless Week Continues

TWLO : 392.88 (+4.05%)
RCII : 57.76 (+5.42%)
SAH : 46.11 (+3.62%)
NVAX : 231.23 (+4.39%)
PHIO : 2.86 (-7.44%)
EBAY : 56.42 (-0.98%)
WHR : 190.08 (+1.04%)
WMT : 129.92 (-1.54%)
CLSK : 23.93 (-2.96%)
BCOV : 21.78 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as...

See More

Key Turning Points

3rd Resistance Point 252.73
2nd Resistance Point 243.08
1st Resistance Point 237.16
Last Price 231.23
1st Support Level 221.59
2nd Support Level 211.94
3rd Support Level 206.02

See More

52-Week High 331.68
Last Price 231.23
Fibonacci 61.8% 207.56
Fibonacci 50% 169.22
Fibonacci 38.2% 130.89
52-Week Low 6.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar